Close Menu

NEW YORK (GenomeWeb) – JP Morgan has downgraded Genomic Health to Underweight from Neutral, citing a slower than expected coverage expansion for the company's prostate cancer test, and a "tepid" outlook for the company's core breast cancer testing business.

The investment bank also lowered the price target on Genomic Health's stock price to $25 from $28.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.